Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Glowing bacteria show researchers how an anti-flu-virus drug may prevent bacterial pneumonia

10.03.2003


Viral enzyme ’clear cuts’ forest of protective molecules on lung cells in mice; blocking that enzyme reduces illness and incidence of death from subsequent infection by Streptococcus pneumoniae



Investigators at St. Jude Children’s Research Hospital have shown in mice how the potentially deadly cooperation between influenza virus and bacterial pneumonia infections can be foiled, even if treatment is delayed and flu virus levels in the lung have peaked.

The St. Jude team showed that the flu virus enzyme neuraminidase (NA) strips lung cells of their protective forest of molecules called sialic acid. The unprotected cells are then vulnerable to subsequent infection with Streptococcus pneumoniae bacteria. But treatment of the mice with the NA-inhibitor drug ostelamivir blocked the activity of flu virus NA and offered significant protection against pneumonia. The study’s findings appear in the March 15 issue of the Journal of Infectious Diseases.


"We previously showed that when Streptococcus pneumoniae was given to mice seven days after they had been infected with flu virus, the mortality was extremely high," said Jonathan McCullers, MD, the lead author of the report. "Our current study using tissue in lab dishes, as well as live mice, showed that viral NA is the key to this deadly synergy between flu virus and pneumonia bacteria. The streptococcus bacteria also have NA," McCullers said, "but it is much less efficient than the viral enzyme in cutting away at the lung cell’s sialic acid barrier."

The St. Jude finding is important because a combined infection with influenza and pneumonia is the sixth leading cause of all deaths worldwide, and is the top cause of death due to an infection, according to McCullers assistant member in the Department of Infectious Diseases at St. Jude. Moreover, the overall death rate associated with pneumonia and influenza increased by 59% between 1979 and 1994, according to a 1996 report in the Journal of the American Medical Association.

"The flu virus targets the sialic acid molecules on the lung cell membrane surface so it can get inside the lung cell and reproduce," McCullers said. "After the virus multiplies inside the cell, the new viruses cut through the sialic acid on the way out."

"By blocking the virus NA we protect the sialic acid molecules covering the lung cells," says McCullers. "That leaves the pneumonia bacteria stranded outside the cells and gives the immune system time to destroy them before they can cause respiratory disease."

In the study, one group of mice received prophylactic (protective) doses of oseltamivir for five days, beginning four hours before being infected with flu virus. Another group got oseltamivir for five days starting 48 hours after being infected with flu.

Mice that received delayed treatment lost weight and had greatly increased levels of virus in their lungs by the time they received oseltamivir. However, these mice still had significant protection against subsequent infection by streptococcus bacteria compared to control mice that received no treatment.

"The key to significantly reducing the rate of death in these mice was not reducing virus levels or maintaining weight," McCullers explains. "What was important was blocking the virus NA enzyme with oseltamivir and preserving the protective sialic acid molecules."

The St. Jude team also studied the effect of oseltamivir on bacterial pneumonia using live mice infected with genetically modified streptococcus. These modified bacteria were engineered to carry on a light-producing chemical reaction--the same chemical reaction used by fireflies. The light, too faint for humans to see, passed through the skin of the mice and was picked up by a special camera.

In mice given flu virus and then the "glowing" streptococcus but no oseltamivir, the camera captured images of extensive bacterial infections throughout the thorax--the part of the body containing the lungs. In mice that also received oseltamivir as a delayed treatment after infection with flu virus, the light emitted from the lungs was less intense and not localized in specific areas. This suggested that the immune system of the infected mice was able to kill many of the bacteria that were "stranded" outside the cell membrane in oseltamivir-treated animals.

Untreated mice developed pneumonia earlier than treated mice and died. In treated mice, even when infection spread, the progression of the disease was slower than in untreated mice, and up to half of the treated animals survived.

When the researchers studied the effect of oseltamivir using human lung cells in a dish, they found that the drug blocked the binding of streptococcus to these cells by interfering with NA, similar to the findings in mice.

The article’s co-author is Rhodes College pre-med student Kimberly A. Bartmess, who works in Dr. McCullers’ lab as a part of the St. Jude – Rhodes Summer Plus Program.


###
This project was supported by the National Institute of Allergy and Infections Diseases at the National Institutes of Health, a Cancer Center Support Grant and ALSAC.

St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital, in Memphis, Tennessee, was founded by the late entertainer Danny Thomas. The hospital is an internationally recognized biomedical research center dedicated to finding cures for catastrophic diseases of childhood. The hospital’s work is supported through funds raised by ALSAC. ALSAC covers all costs not covered by insurance for medical treatment rendered at St. Jude Children’s Research Hospital. Families without insurance are never asked to pay. For more information, please visit www.stjude.org.

Bonnie Cameron | EurekAlert!
Further information:
http://www.stjude.org/

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Organ Crosstalk: Fatty Liver Can Cause Damage to Other Organs

18.08.2017 | Life Sciences

Gold shines through properties of nano biosensors

17.08.2017 | Physics and Astronomy

Greenland ice flow likely to speed up: New data assert glaciers move over sediment, which gets more slippery as it gets wetter

17.08.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>